Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 1:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 108 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Blinded Study Medication - Condition 2 Clear all
Completed Phase 4 Interventional

Stress Ulcer Prophylaxis Versus Placebo in Critically Ill Infants With Congenital Heart Disease

NCT03667703
View directory record Official record
Conditions
Congenital Heart Disease, Upper Gastrointestinal Bleeding, Stress Ulcer, Infection
Interventions
Famotidine, Placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
1 Minute to 12 Months
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Oct 21, 2026, 1:09 AM EDT
Completed Phase 2 Interventional Results available

31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Parkinson's Disease

NCT03815916
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Gold Nanocrystals
Drug
Lead sponsor
Clene Nanomedicine
Industry
Eligibility
30 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 21, 2026, 1:09 AM EDT
Completed Phase 4 Interventional Results available

Trigger Point Injections in Anterior Cervical Surgery

NCT04640896
View directory record Official record
Conditions
Myofacial Pain, Pain, Neck, Pain, Back, Cervical Fusion
Interventions
Trigger point injection with bupivacaine, Trigger point injection with normal saline, Lidocaine skin wheal
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 21, 2026, 1:09 AM EDT
Recruiting Phase 4 Interventional

Predictors of Improvements in Irritability and Aggression in Children With ADHD Treated With CNS Stimulants

NCT06871488
View directory record Official record
Conditions
ADHD - Attention Deficit Disorder With Hyperactivity, Irritability, Aggression Childhood
Interventions
CNS Stimulant, Placebo, CNS Stimulant open label first phase
Drug · Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
7 Years to 12 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 21, 2026, 1:09 AM EDT
Completed Phase 2 Interventional Results available

Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

NCT00963105
View directory record Official record
Conditions
Relapsed or Refractory Chronic Lymphocytic Leukemia
Interventions
lenalidomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
16
States / cities
La Jolla, California • Rancho Mirage, California • Stanford, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Oct 21, 2026, 1:09 AM EDT
Completed Phase 3 Interventional Results available

Effects of Adalimumab on Mucosal Healing in Subjects With Crohn's Disease Involving the Colon

NCT00348283
View directory record Official record
Conditions
Crohn's Disease
Interventions
adalimumab, placebo
Biological
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 75 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
7
States / cities
Atlanta, Georgia • Chicago, Illinois • Chevy Chase, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2011 · Synced Oct 21, 2026, 1:09 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Effect of the Combination of Umeclidinium (UMEC) and Vilanterol (VI) on Exercise Endurance Time (EET) in Participants With Chronic Obstructive Pulmonary Disease (COPD)

NCT02275052
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
UMEC/VI DPI, Placebo DPI, Albuterol/salbutamol MDI
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
10
States / cities
Jasper, Alabama • Saint Charles, Missouri • Charlotte, North Carolina + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Oct 21, 2026, 1:09 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis

NCT04373317
View directory record Official record
Conditions
Parkinson's Disease Psychosis
Interventions
Pimavanserin, Quetiapine
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years and older
Enrollment
358 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
24
States / cities
Tucson, Arizona • Loma Linda, California • Palo Alto, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 21, 2026, 1:09 AM EDT
Completed Phase 3 Interventional Results available

A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)

NCT00900731
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Indacaterol 150 μg, Tiotropium 18 μg, Placebo to indacaterol, Placebo to tiotropium
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
1,598 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
25
States / cities
Birmingham, Alabama • Jasper, Alabama • Phoenix, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2011 · Synced Oct 21, 2026, 1:09 AM EDT
Completed Phase 2 Interventional Results available

Phase II Randomized Trial:Arginine Butyrate Plus Standard Local Therapy in Patients With Refractory Sickle Cell Ulcers

NCT00004412
View directory record Official record
Conditions
Skin Ulcers, Sickle Cell Anemia
Interventions
Arginine Butyrate, Standard local care dressing
Drug · Other
Lead sponsor
Susan P. Perrine
Other
Eligibility
16 Years to 60 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2005
U.S. locations
4
States / cities
Chicago, Illinois • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced Oct 21, 2026, 1:09 AM EDT
Active, not recruiting Phase 2 Interventional

Project 1 Aim 2, Adaptations of the Brain in Chronic Pain With Opioid Exposure

NCT05463367
View directory record Official record
Conditions
Opioid Use, Opioid Dependence, Opioid-use Disorder, Narcotic Use, Back Pain, Back Injuries, Chronic Pain, Chronic Low-back Pain, Pain, Chronic, Pain;Back Low;Chronic, Pain, Back
Interventions
Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet, Naproxen 500 Mg, Opioids
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 21, 2026, 1:09 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders

NCT01456936
View directory record Official record
Conditions
Smoking Cessation
Interventions
Placebo, varenicline tartrate, bupropion hydrochloride, Nicotine Replacement Therapy Patch
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
8,144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
77
States / cities
Mobile, Alabama • Phoenix, Arizona • Encino, California + 61 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2016 · Synced Oct 21, 2026, 1:09 AM EDT
Terminated Phase 2 Interventional Results available

Use of a Novel Drug in People With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease (NAFLD)

NCT02605616
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH)
Interventions
AZ compound, Placebo
Drug · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
21 Years to 75 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 1, 2024 · Synced Oct 21, 2026, 1:09 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease

NCT02760433
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Olokizumab, Placebo
Drug
Lead sponsor
R-Pharm International, LLC
Industry
Eligibility
18 Years and older
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
50
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • Covina, California + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 21, 2026, 1:09 AM EDT
Completed Phase 4 Interventional Results available

Study to Assess Changes in the Immune Profile in Adults With Early Rheumatoid Arthritis

NCT02557100
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept, Adalimumab, Methotrexate
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
21
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Oct 21, 2026, 1:09 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment

NCT02055118
View directory record Official record
Conditions
Hunter Syndrome
Interventions
idursulfase-IT, No IT treatment
Biological · Other
Lead sponsor
Shire
Industry
Eligibility
Up to 18 Years · Male only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Oakland, California • Chicago, Illinois • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 21, 2026, 1:09 AM EDT
Completed Phase 3 Interventional Results available

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer

NCT02631876
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Ovarian Cancer
Interventions
Mirvetuximab soravtansine, Paclitaxel, Pegylated liposomal doxorubicin, Topotecan
Drug
Lead sponsor
ImmunoGen, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
53
States / cities
Birmingham, Alabama • Tempe, Arizona • Tucson, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2020 · Synced Oct 21, 2026, 1:09 AM EDT
Completed Not applicable Interventional Results available

The Effect and Safety of a Novel CGM-Based Titration Algorithm for Basal Insulin in T2DM Participants.

NCT06111508
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Continuous Glucose Monitoring (CGM)-based titration algorithm implemented in DiAs
Device
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
New York, New York • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 21, 2026, 1:09 AM EDT
Completed Phase 4 Interventional Results available

Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects

NCT05548647
View directory record Official record
Conditions
Obesity
Interventions
Behavioral Treatment, Placebo, Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY]
Behavioral · Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 21, 2026, 1:09 AM EDT
Terminated Phase 3 Interventional Results available

Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease

NCT03615924
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Ticagrelor, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
2 Years to 17 Years
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
7
States / cities
Fort Lauderdale, Florida • Miami, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2021 · Synced Oct 21, 2026, 1:09 AM EDT
Completed Not applicable Interventional Results available

Cirrhosis Medical Home

NCT04581369
View directory record Official record
Conditions
Cirrhosis, Liver
Interventions
Care Coordinator Intervention for Direct Intervention Group, Care Coordinator Intervention for Standard of Care Group, Caregiver Intervention
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced Oct 21, 2026, 1:09 AM EDT
Completed Phase 3 Interventional Results available

Treatment Effects of Escitalopram (Lexapro®) on Generalized Anxiety Disorder in Patients With HIV and AIDS

NCT00887679
View directory record Official record
Conditions
Anxiety Disorders, HIV Infections
Interventions
Escitalopram
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 31, 2014 · Synced Oct 21, 2026, 1:09 AM EDT
Recruiting Phase 2 Interventional

Repurposing Semaglutide for the Treatment of Cocaine Use Disorder

NCT07227948
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
Semaglutide, Placebo, cognitive behavioral therapy (CBT).
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 21, 2026, 1:09 AM EDT
Completed Phase 3 Interventional Results available

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)

NCT01321554
View directory record Official record
Conditions
Thyroid Cancer
Interventions
Lenvatinib, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
38
States / cities
Little Rock, Arkansas • La Jolla, California • Los Gatos, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 21, 2026, 1:09 AM EDT